Activated oncogenes and putative tumor suppressor genes involved in human breast cancers
- 1 January 1993
- book chapter
- Published by Springer Nature
- Vol. 63, 15-60
- https://doi.org/10.1007/978-1-4615-3088-6_2
Abstract
The clinical progression of human breast cancer almost certainly reflects accumulated molecular defects in specific genes that are important in regulating normal breast tissue growth and development. These specific defects may occur in association with gross chromosomal damage and aberrations in total cellular DNA content, once providing the only basis for their genetic detection. Within the past decade, however, new molecular techniques have enabled the detection of an increasing number of genetic abnormalities that are specific to malignant cells but not necessarily unique to breast cancers. Some of these molecular defects found in the earliest stages of human breast cancer (e.g., c-erbB-2 amplification) appear to have clinical significance by their ability to predict tumor relapse and patient survival, suggesting that they produce permanent cellular disturbances contributing to the proliferative or invasive nature of breast cancer. Nonetheless , a unified molecular model explaining breast carcinogenesis and its clinical progression is far from being realized. As this review demonstrates, we have only begun to identify and characterize clinically significant genetic abnormalities as they are found in primary human breast cancers. At present, it is useful to classify these molecular abnormalities into two types: gain-of-function genetic events that activate proto-oncogenes by DNA mutation, rearrangement, or amplification, and loss-of-function defects reflecting putative tumor suppressor genes that have been inactivated by DNA mutation and unmasked by deletion or allelic loss.Keywords
This publication has 237 references indexed in Scilit:
- Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinomain situBreast Cancer Research and Treatment, 1991
- Preferential involvement of 11q23–24 and 11p15 in breast cancerCancer Genetics and Cytogenetics, 1991
- Long‐term survival in breast cancer related to overexpression of the c‐erbB‐2 oncoprotein: An immunohistochemical study using monoclonal antibody NCL‐CB11The Journal of Pathology, 1991
- The H-ras oncogene product p21 and prognosis in human breast cancerBreast Cancer Research and Treatment, 1991
- Two homologous oncogenes, HST1 and INT2, are closely located in human genomeBiochemical and Biophysical Research Communications, 1988
- Expression of p21ras gene products in breast cancer relates to histological types and to receptor and nodal statusBreast Cancer Research and Treatment, 1988
- Distribution of Ha-RAS-1 proto-oncogene alleles in breast cancer patients and in a control populationBreast Cancer Research and Treatment, 1988
- Monoclonal antibody DF3 correlates with tumor differentiation and hormone receptor status in breast cancer patientsBreast Cancer Research and Treatment, 1985
- Cytogenetic and molecular biologic alterations in human breast cancer: A reviewBreast Cancer Research and Treatment, 1985
- Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodiesCell, 1985